NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 1 நாளுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Haleos Labs Standalone Q2 Net Profit Down 13.4% YoY to ₹4.31 Cr; Approves Strategic Alliance
Haleos Labs reported its Q2 FY27 (quarter ended September 30, 2026) results with standalone revenue from operations rising 13.3% YoY to ₹88.20 crore (vs ₹77.84 crore in Q2 FY26). However, standalone net profit fell 13.4% YoY to ₹4.31 crore (from ₹4.98 crore) due to higher operating and material costs, though it recovered sequentially from ₹3.24 crore in Q1. Subsidiary Mahi Drugs posted a quarterly net loss of ₹3.74 crore on revenue of ₹8.30 crore. Additionally, the Board granted in-principle approval for a strategic alliance with HRV Global Life Sciences for R&D, contract manufacturing, and commercialization.
உச்சம் நம்பிக்கை
என்ன மாறியதுApproved Q2 and H1 FY27 financial results and gave in-principle approval for a strategic collaboration with HRV Global Life Sciences.
ஏன் இது முக்கியம்Shows operational top-line recovery YoY but compressed standalone margins and ongoing subsidiary losses weighing on consolidated profitability.
Standalone Revenue (Q2): ₹8,820.38 லட்சம்Standalone PAT (Q2): ₹431.14 லட்சம்Mahi Drugs Q2 Net Loss: ₹373.91 லட்சம்Standalone H1 Net Profit: ₹754.92 லட்சம்
📅 குறுகிய காலம்Market reaction may be muted to slightly cautious given the YoY net profit contraction and dragging subsidiary losses despite topline expansion.
📈 நீண்ட காலம்Collaborations like HRV Global Life Sciences align with management's goal to expand into niche API products, but turnaround of subsidiary operations remains critical.
⚠ அபாய எச்சரிக்கைகள்
Subsidiary Mahi Drugs continues to generate losses (₹3.74 Cr loss in Q2)
Definitive terms and financial scope of HRV Global Life Sciences alliance are not yet executed
👀 கவனிக்க வேண்டியவை
Track the execution of the definitive agreement with HRV Global Life Sciences and monitor whether subsidiary Mahi Drugs can reduce operating losses in upcoming quarters.
Haleos Labs Clears USFDA Inspection with Zero Form 483 Observations at Mahi Drugs Unit
The USFDA successfully completed an inspection of Mahi Drugs Private Limited, a material subsidiary of Haleos Labs Limited, from September 15 to September 18, 2026. The inspection concluded with zero Form 483 observations, replicating the clean outcome of the previous inspection in January 2025. This facility is located at Jawaharlal Nehru Pharma City, Parawada, Andhra Pradesh, and produces active pharmaceutical ingredients (APIs). A zero-observation outcome reduces compliance uncertainty and supports the company's US-focused supply plans against its TTM revenue base of Rs 332 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுUSFDA concluded its audit of Mahi Drugs Private Limited with zero observations, confirming ongoing GMP compliance.
ஏன் இது முக்கியம்A clean USFDA inspection removes regulatory risks of import alerts or warning letters, safeguarding exports to the lucrative US market.
Form 483 Observations: 0Inspection Period: செப்டம்பர் 15, 2026 to செப்டம்பர் 18, 2026Previous Inspection Date: ஜனவரி 24, 2025TTM Revenue Context: Rs 332 கோடி
📅 குறுகிய காலம்Positive sentiment driver as regulatory overhang from an active audit is cleared without any compliance remedial actions required.
📈 நீண்ட காலம்Reaffirms the company's US compliance status, enabling continued API supply and potential new DMF filings to support its 50+ product target by FY2028.
⚠ அபாய எச்சரிக்கைகள்
Formal Establishment Inspection Report (EIR) issuance remains the final administrative closure step.
👀 கவனிக்க வேண்டியவை
Track the formal receipt of the Establishment Inspection Report (EIR) from the USFDA and subsequent product launch or export traction from this facility in regulated markets.
Haleos Labs Appoints ChemWerth President Vincent P. Asaro as Nominee Director for Mahi Drugs
Haleos Labs Limited has announced key changes at its material subsidiary, Mahi Drugs Private Limited, effective August 5, 2026. Mr. Vincent P. Asaro, the President of ChemWerth Inc. (a global API developer), has been appointed as a Nominee Director, replacing Mr. M. Madhu Rao. This appointment brings over 35 years of international pharmaceutical and financial expertise to the subsidiary's board. Additionally, Annapragada & Co. has been appointed as the Cost Auditor for the subsidiary for the 2026-27 financial year.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe material subsidiary Mahi Drugs has replaced its Nominee Director with the President of its global partner ChemWerth Inc. and appointed new cost auditors.
ஏன் இது முக்கியம்Having the head of a global API supplier on the board of a material subsidiary strengthens strategic ties and provides high-level expertise for navigating regulated international markets, which is critical for Haleos' goal of reaching 50+ products by FY2028.
Director Experience: 35 yearsCost Audit Period: FY 2026-27TTM வருவாய்: Rs 348 கோடிசந்தை மதிப்பு: Rs 507 கோடி
📅 குறுகிய காலம்The appointment is likely to be viewed positively by the market as it signals professionalization and stronger global linkages for the subsidiary.
📈 நீண்ட காலம்This move supports the company's structural shift toward complex, niche APIs and regulated market expansion by leveraging ChemWerth's global presence.
👀 கவனிக்க வேண்டியவை
Investors should monitor if this board-level alignment with ChemWerth leads to increased order flow or faster approvals in regulated markets like the USA and Brazil, which are key parts of the company's FY2028 growth strategy.
Haleos Labs Q1 FY27: Net Profit Drops 36% YoY to ₹2.65 Cr on 11.6% Revenue Decline
Haleos Labs Limited (formerly SMS Lifesciences) reported a weak set of consolidated results for Q1 FY27. Revenue from operations declined 11.6% YoY to ₹72.94 Cr, while net profit attributable to the parent fell 36.3% YoY to ₹2.65 Cr. The decline is notable as cost of materials consumed rose to ₹40.14 Cr from ₹27.73 Cr in the year-ago period, despite the lower topline, indicating significant margin pressure. On a sequential basis, profit improved from a very low base of ₹0.44 Cr in Q4 FY26, but remains well below historical averages.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a period of higher profitability to one of margin compression, with a double-digit decline in revenue and a significant spike in raw material costs as a percentage of sales.
ஏன் இது முக்கியம்As a global leader in Ranitidine Hcl, the company's high product concentration makes it vulnerable to pricing and demand shifts; these results suggest a challenging environment for its core API portfolio.
Consolidated Revenue (Q1 FY27): ₹72.94 கோடிNet Profit (Attributable to Parent): ₹2.65 கோடிYoY Revenue Growth: -11.6%YoY PAT Growth: -36.3%EPS (Q1 FY27): ₹8.75Revenue vs TTM Revenue: ~21%
📅 குறுகிய காலம்The stock may face downward pressure in the short term as the market reacts to the YoY contraction in both scale and profitability.
📈 நீண்ட காலம்The long-term outlook depends on the successful execution of backward integration and expansion into niche APIs to mitigate the current high concentration risk and margin volatility.
⚠ அபாய எச்சரிக்கைகள்
High product concentration (Ranitidine Hcl)
Significant increase in raw material costs
Fragmented industry pricing pressure
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to pass on rising raw material costs and track the progress of its product diversification strategy, aiming for 50+ products by FY2028 to reduce reliance on Ranitidine Hcl.
Haleos Labs Promoters Declare Zero Encumbrance of Shares for FY 2025-26
TVVSN Murthy, representing the promoter and promoter group of Haleos Labs Limited, has filed an annual disclosure under Regulation 31(4) of SEBI SAST Regulations. The declaration confirms that no shares held by the promoter group were encumbered or pledged, directly or indirectly, during the financial year ended March 31, 2026. The disclosure lists 15 promoter entities, including major shareholders like Hima Bindu Potluri (7,42,436 shares) and TVVSN Murthy (4,80,034 shares). This filing serves as a confirmation of the financial stability of the promoters regarding their equity holdings.
முக்கிய அம்சங்கள்
Promoter group confirms zero shares are pledged or encumbered as of the year ended March 31, 2026.Compliance filing made under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.Major individual holdings disclosed include Hima Bindu Potluri (7,42,436 shares) and TVVSN Murthy (4,80,034 shares).Other significant promoter holdings include Rajeswara Rao Gopineedi with 2,73,939 shares and Ramesh Babu Potluri with 2,40,190 shares.A total of 15 promoter and promoter group entities are covered under this non-encumbrance declaration.
👀 கவனிக்க வேண்டியவை
Investors can take comfort in the fact that there is zero promoter pledge, which reduces the risk of forced selling during market volatility. No immediate action is required as this is a routine annual regulatory disclosure.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Haleos Labs Limited has recommended a final dividend of Rs 1.50 (15%) per equity share for FY2025-26. The company's annual standalone revenue declined to Rs 300.99 crore from Rs 333.37 crore in the previous year. Net profit for the full year also saw a contraction, falling to Rs 17.78 crore from Rs 21.37 crore. Alongside results, the company announced the resignation of an independent director and the reappointment of a Whole-time Director for five years.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs 1.50 per equity share of Rs 10 face value.Annual standalone revenue decreased by 9.7% YoY to Rs 30,098.96 Lakhs.Standalone Net Profit for FY26 fell to Rs 1,777.68 Lakhs compared to Rs 2,137.08 Lakhs in FY25.Q4 FY26 revenue dropped significantly to Rs 6,338.42 Lakhs from Rs 8,542.78 Lakhs in the year-ago quarter.Earnings Per Share (EPS) for the full year decreased to Rs 58.80 from Rs 70.69.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the dividend payout comes amid declining revenue and profitability. Monitor the company's ability to arrest the top-line slide and the impact of the upcoming statutory auditor change.
Haleos Labs Credit Rating Reaffirmed at IVR BBB/Positive; Rated Facilities Enhanced to ₹116 Cr
Infomerics Valuation and Rating Limited has reaffirmed the credit ratings for Haleos Labs Limited and its material subsidiary, Mahi Drugs Private Limited. The company's long-term rating is maintained at IVR BBB with a 'Positive' outlook, while the short-term rating remains IVR A3+. Significantly, the total rated bank loan facilities for the parent company have been enhanced from ₹81.86 crore to ₹116.01 crore, indicating increased borrowing capacity for operations or expansion.
முக்கிய அம்சங்கள்
Long-term rating reaffirmed at IVR BBB with a 'Positive' outlook for Haleos Labs Limited.Short-term rating reaffirmed at IVR A3+ for fund-based and non-fund based bank facilities.Total rated bank loan facilities for the company increased from ₹81.86 crore to ₹116.01 crore.Material subsidiary Mahi Drugs Private Limited's rated facilities enhanced to ₹20.75 crore with IVR BB+/Stable rating.Ratings assessment included operational and financial performance data up to 9MFY26.
👀 கவனிக்க வேண்டியவை
The 'Positive' outlook indicates a potential for a rating upgrade in the medium term if financial performance stays robust. Investors should monitor the company's ability to service the increased debt levels as it utilizes the enhanced bank facilities.
Haleos Labs Seeks Approval for ₹20 Crore Corporate Guarantee for Subsidiary Mahi Drugs
Haleos Labs Limited has issued a postal ballot notice to seek shareholder approval for a material related party transaction. The company intends to provide a corporate guarantee of up to USD 2.2 million (approximately ₹20 crores) in favor of RBL Bank. This guarantee is required to secure an External Commercial Borrowing (ECB) facility for its subsidiary, Mahi Drugs Private Limited. Shareholders can cast their votes via remote e-voting between March 31 and April 29, 2026.
முக்கிய அம்சங்கள்
Proposed corporate guarantee of USD 2.2 million (approx. ₹20 crores) for subsidiary Mahi Drugs Private LimitedGuarantee to secure External Commercial Borrowing (ECB) facility from RBL BankShareholder approval sought via postal ballot through remote e-voting processE-voting period scheduled from March 31, 2026, to April 29, 2026Final results of the postal ballot to be declared on May 1, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the parent company's contingent liabilities and the performance of Mahi Drugs to ensure the debt is well-serviced. This move indicates financial support for subsidiary expansion but increases the parent's risk profile.
Haleos Labs Seeks Shareholder Approval for Corporate Guarantee to Subsidiary Mahi Drugs
Haleos Labs Limited has initiated a Postal Ballot process to seek shareholder approval for a material related party transaction. The company intends to provide a corporate guarantee to RBL Bank to secure External Corporate Borrowing (ECB) facilities for its subsidiary, Mahi Drugs Private Limited. The e-voting period is scheduled to run from March 31, 2026, to April 29, 2026, with final results to be declared on May 1, 2026. This move highlights the parent company's financial support for its subsidiary's capital requirements.
முக்கிய அம்சங்கள்
Proposed ordinary resolution for a corporate guarantee to RBL Bank for subsidiary Mahi Drugs Private Limited.The transaction is categorized as a Material Related Party Transaction under SEBI regulations.Cut-off date for shareholder voting eligibility is March 27, 2026.E-voting window is open for 30 days from March 31 to April 29, 2026.Postal ballot results will be officially declared on May 1, 2026.
👀 கவனிக்க வேண்டியவை
Investors should evaluate the financial health of the subsidiary, Mahi Drugs, as this guarantee increases the contingent liabilities of Haleos Labs. Monitor the final voting results on May 1 to confirm the approval of this financial arrangement.
Haleos Labs Q3 FY26 Consolidated Net Profit Rises 37% YoY to ₹6.65 Cr; Revenue Up 12%
Haleos Labs Limited (formerly SMS Lifesciences) reported a strong consolidated performance for Q3 FY26, with revenue growing 12% YoY to ₹94.78 crore. Consolidated net profit surged 37% YoY to ₹6.65 crore, driven by improved operational efficiencies and lower finance costs. The board also approved a corporate guarantee for its subsidiary, Mahi Drugs, to facilitate External Commercial Borrowing (ECB), indicating potential expansion plans. While standalone revenue saw a slight dip, the consolidated numbers reflect robust growth from subsidiary operations.
முக்கிய அம்சங்கள்
Consolidated Revenue from Operations increased 12% YoY to ₹94.78 crore from ₹84.60 crore.Consolidated Net Profit grew 37% YoY to ₹6.65 crore compared to ₹4.85 crore in Q3 FY25.Consolidated EPS rose to ₹21.89 for the quarter, up from ₹18.08 in the corresponding previous year quarter.Finance costs on a consolidated basis decreased to ₹1.54 crore from ₹2.14 crore YoY.Board approved a corporate guarantee for subsidiary Mahi Drugs for External Commercial Borrowing, subject to shareholder approval.
👀 கவனிக்க வேண்டியவை
Investors should view the strong consolidated profit growth and debt reduction in finance costs as positive indicators. Monitor the upcoming postal ballot regarding the corporate guarantee for Mahi Drugs as it signals future capital expenditure or expansion.
Haleos Labs Partners with HRV Global for Orphan Drug and Niche API Manufacturing
Haleos Labs Limited has entered into a strategic development collaboration with HRV Global Life Sciences to accelerate the manufacturing of orphan drugs and niche therapeutic APIs. The partnership combines Haleos' USFDA-GMP aligned manufacturing expertise with HRV Global's international regulatory and market access capabilities. This initiative targets high-value, underserved therapeutic segments in major regulated markets including the US and EU. The collaboration is designed to strengthen the company's global footprint across Latin America, MENA, and APAC regions through coordinated development pathways.
முக்கிய அம்சங்கள்
Strategic collaboration with HRV Global Life Sciences for orphan drug and niche therapeutic APIsLeverages Haleos' USFDA-GMP manufacturing systems for high-value complex moleculesTargets expansion into regulated and semi-regulated markets including US, EU, and Latin AmericaFocuses on underserved therapeutic segments to improve product mix and marginsHRV Global to lead regulatory execution and global market access initiatives
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive move toward high-margin niche segments; monitor for specific product pipeline updates and regulatory filings in the US and EU markets.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
